| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $383,888,198 | 7 | 100 |
| Morris Arlene | director | 0 | $0 | 1 | $1.69M | $-1.69M |
| Kearns Evan | Chief Legal Officer | 0 | $0 | 1 | $2.52M | $-2.52M |
| Green John L. | Chief Financial Officer | 0 | $0 | 1 | $2.98M | $-2.98M |
| Sachs Jessica | Chief Medical Officer | 0 | $0 | 1 | $3.2M | $-3.2M |
| Robinson John Edward | Chief Scientific Officer | 0 | $0 | 1 | $3.49M | $-3.49M |
| Fairmount Funds Management LLC | director | 0 | $0 | 2 | $370.02M | $-370.02M |
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the …
Over the last 12 months, insiders at Cogent Biosciences, Inc. have bought $0 and sold $383.89M worth of Cogent Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Cogent Biosciences, Inc. have bought $14.94M and sold $383.89M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,777,777 shares for transaction amount of $25M was made by Fairmount Funds Management LLC (director) on 2025‑07‑10.
| 2026-08-27 | Sale | Morris Arlene | director | 45,510 0.0266% | $37.12 | $1.69M | -14.83% | |
| 2026-03-31 | Sale | Fairmount Funds Management LLC | director | 7M 3.8826% | $34.66 | $242.62M | -8.79% | |
| 2026-01-22 | Sale | Fairmount Funds Management LLC | director | 3.5M 2.1196% | $36.40 | $127.4M | -8.73% | |
| 2025-12-26 | Sale | Robinson John Edward | Chief Scientific Officer | 90,000 0.063% | $38.74 | $3.49M | -7.18% | |
| 2025-12-26 | Sale | Sachs Jessica | Chief Medical Officer | 82,642 0.0577% | $38.70 | $3.2M | -7.18% | |
| 2025-12-26 | Sale | Green John L. | Chief Financial Officer | 77,000 0.0538% | $38.68 | $2.98M | -7.18% | |
| 2025-12-26 | Sale | Kearns Evan | Chief Legal Officer | 65,000 0.0454% | $38.70 | $2.52M | -7.18% | |
| 2025-07-10 | Fairmount Funds Management LLC | director | 2.78M 2.0237% | $9.00 | $25M | +220.55% | ||
| 2025-01-14 | Pinnow Cole | Chief Commercial Officer | 43,750 0.0412% | $7.60 | $332,413 | +48.98% | ||
| 2023-06-09 | Fairmount Funds Management LLC | 10 percent owner | 800,000 0.9139% | $12.00 | $9.6M | -33.60% | ||
| 2022-06-16 | Fairmount Funds Management LLC | 1.2M 0.9424% | $8.25 | $9.9M | +55.51% | |||
| 2021-04-26 | Sale | Green John L. | Chief Financial Officer | 17,813 0.015% | $8.86 | $157,823 | -6.66% | |
| 2020-05-12 | Sale | CAMPANA DARIO | 10 percent owner | 98,200 0.0043% | $0.46 | $45,545 | +429.08% | |
| 2020-05-11 | Sale | CAMPANA DARIO | 10 percent owner | 100,000 0.0043% | $0.46 | $45,496 | +440.83% | |
| 2020-05-08 | Sale | CAMPANA DARIO | 10 percent owner | 100,000 0.0044% | $0.46 | $46,390 | +433.33% | |
| 2020-05-07 | Sale | CAMPANA DARIO | 10 percent owner | 100,000 0.0039% | $0.41 | $41,430 | +482.93% | |
| 2020-05-06 | Sale | CAMPANA DARIO | 10 percent owner | 1,800 <0.0001% | $0.40 | $722 | +524.04% | |
| 2020-05-05 | Sale | CAMPANA DARIO | 10 percent owner | 135,484 0.0052% | $0.40 | $54,437 | +508.44% | |
| 2020-05-04 | Sale | CAMPANA DARIO | 10 percent owner | 4,795 0.0002% | $0.40 | $1,921 | +508.44% | |
| 2020-05-01 | Sale | CAMPANA DARIO | 10 percent owner | 800 <0.0001% | $0.41 | $328 | +506.21% |
| Fairmount Funds Management LLC | director | 5503418 3.1715% | $170.94M | 3 | 2 | +138.03% |
| FROST PHILLIP MD ET AL | 15734874 9.0678% | $488.73M | 6 | 0 | ||
| Schulke Ryan | Chief Executive Officer | 6364537 3.6678% | $197.68M | 9 | 0 | +150.58% |
| Conlin Matthew | President | 4437980 2.5575% | $137.84M | 7 | 0 | +150.58% |
| Booth Bruce | director | 3361535 1.9372% | $104.41M | 1 | 0 | <0.0001% |
| Atlas Venture Fund IX, L.P. | 10 percent owner | 3361535 1.9372% | $104.41M | 1 | 0 | <0.0001% |
| Ratcliffe Liam | director | 897773 0.5174% | $27.88M | 1 | 0 | <0.0001% |
| Dubner Derek | Chief Executive Officer | 589513 0.3397% | $18.31M | 4 | 3 | |
| FMR LLC | 452115 0.2605% | $14.04M | 1 | 0 | <0.0001% | |
| Fried Robert N | director | 337338 0.1944% | $10.48M | 1 | 0 | |
| Jordan Harry Baker III | Chief Operating Officer | 110000 0.0634% | $3.42M | 4 | 0 | |
| Pinnow Cole | Chief Commercial Officer | 45848 0.0264% | $1.42M | 1 | 0 | +48.98% |
| MacLachlan Daniel | Chief Financial Officer | 3500 0.002% | $108,710.00 | 2 | 3 | |
| BOLGER JOHN C | director | 0 0% | $0 | 1 | 3 |
$67,892,722 | 138 | 28.28% | $6.25B | |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$11,583,737 | 45 | 49.75% | $4.66B | |
$477,065,869 | 34 | 82.05% | $6B |
| Increased Positions | 187 | +94.92% | 43M | +27.08% |
| Decreased Positions | 90 | -45.69% | 29M | -18.06% |
| New Positions | 95 | New | 15M | New |
| Sold Out Positions | 23 | Sold Out | 6M | Sold Out |
| Total Postitions | 294 | +49.24% | 174M | +9.01% |
| Fmr Llc | $778,463.00 | 14.74% | 22.41M | +5M | +31.21% | 2025-09-30 |
| Blackrock, Inc. | $360,238.00 | 6.82% | 10.37M | +2M | +20.2% | 2025-09-30 |
| Deerfield Management Company, L.P. | $314,505.00 | 5.96% | 9.05M | +6M | +242.89% | 2025-09-30 |
| Fairmount Funds Management Llc | $312,779.00 | 5.92% | 9M | +3M | +44.62% | 2025-09-30 |
| Kynam Capital Management, Lp | $273,966.00 | 5.19% | 7.89M | -606,385 | -7.14% | 2025-09-30 |
| Vanguard Group Inc | $269,501.00 | 5.1% | 7.76M | +1M | +18.93% | 2025-09-30 |
| Commodore Capital Lp | $251,865.00 | 4.77% | 7.25M | +5M | +213.69% | 2025-09-30 |
| Tcg Crossover Management, Llc | $236,168.00 | 4.47% | 6.8M | -166,213 | -2.39% | 2025-09-30 |
| State Street Corp | $165,898.00 | 3.14% | 4.78M | +1M | +41.62% | 2025-09-30 |
| Vr Adviser, Llc | $138,960.00 | 2.63% | 4M | -755,411 | -15.88% | 2025-09-30 |